Sulfequine 333 mg/g + 67 mg/g oral paste for horses

Authorised

- Sulfadiazine
- Trimethoprim

Product identification

Medicine name:
Sulfequine 333 mg/g + 67 mg/g oral paste for horses
SULFEQUINE 333 MG/G + 67 MG/G PATE ORALE POUR CHEVAUX

Active substance:
Sulfadiazine
Trimethoprim

Target species:
Horse

Route of administration:
Oral use

Product details

Active substance and strength:
Sulfadiazine
333.00 milligram(s) / 1.00 gram(s)

Trimethoprim
67.00 milligram(s) / 1.00 gram(s)

Pharmaceutical form:
Oral paste

Withdrawal period by route of administration:
Oral use:

- **Horse**
  - Meat and offal. 15 day — For a treatment period of up to 5 days
  - Meat and offal. 6 month — For a treatment period of more than 5 days

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QJ01EW10

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
France

Package description:
Cardboard box containing 1 oral syringe containing 45 grams paste
Cardboard box containing 5 oral syringes containing 45 grams paste
Cardboard box containing 6 oral syringes containing 45 grams paste
Cardboard box containing 10 oral syringes containing 45 grams paste
Cardboard box containing 1 oral syringe containing 52.5 grams paste
Cardboard box containing 5 oral syringes containing 52.5 grams paste
Cardboard box containing 6 oral strings containing 52.5 grams paste
Cardboard box containing 10 oral syringes containing 52.5 grams paste

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Hybrid application (Article 19(1) of Regulation (EU) 2019/6)

Marketing authorisation holder:
CP-Pharma Handelsgesellschaft mbH

Marketing authorisation date:
4/07/2025

Manufacturing sites for batch release:
CP-Pharma Handelsgesellschaft mbH

Responsible authority:
French Agency For Food, Environmental And Occupational Health & Safety

Authorisation number:
FR/V/7364950 2/2025

Date of authorisation status change:
4/07/2025

Reference member state:
Netherlands

Procedure number:
NL/V/0428/001/DC

Concerned member states:
Austria Belgium Czechia Denmark Estonia France Germany Greece Hungary Ireland Italy Latvia Lithuania Norway Poland Portugal Slovakia Spain Sweden United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.

Package Leaflet and Labelling

This document does not exist in this language (English). You can find it in another language below.